Journal of Clinical Oncology, Vol 14, 2197-2205, Copyright © 1996 by American Society of Clinical Oncology

ARTICLES

Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer

PA Greenberg, GN Hortobagyi, TL Smith, LD Ziegler, DK Frye and AU Buzdar
Department of Breast Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, USA.

PURPOSE: To determine the long-term clinical course of patients with metastatic breast cancer (MBC) who achieved a complete remission with doxorubicin-alkylating agent-containing combination chemotherapy programs. PATIENTS AND METHODS: To assess the long-term prognosis of MBC, we reviewed our experience with 1,581 patients treated on consecutive doxorubicin and alkylating agent-containing front-line treatment protocols between 1973 and 1982. Treatment was administered for a maximum duration of 2 years. Characteristics of long-term survivors were evaluated, and hazard rates for progression were calculated. RESULTS: From this group, 263 (16.6%) achieved complete responses (CR) and 49 (3.1%) remained in CR for more than 5 years. After a median duration of 191 months, 26 patients remain in first CR, four patients died in CR at times ranging from 118 to 234 months, 18 patients died of breast cancer, and one is alive with metastatic disease. Compared with the overall CR and total patient populations, the long-term CR group had more premenopausal patients, a younger median age, a lower tumor burden, and better performance status. The hazard function shows a substantial drop in risk of progression after approximately 3 years from initiation of therapy. Ten long-term CR patients developed second primary cancers: breast (3), ovary (2), pancreas (1), endometrium (1), colon (1), head and neck (1), and lung (1). CONCLUSION: Most patients with MBC treated with systemic therapies have only temporary responses to treatment, but some patients continue in CR following initial treatment. These data show that a small percentage of patients achieve long-term remissions with standard chemotherapy regimens. Remission consolidation strategies are needed.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M.-Y. Wang, P.-S. Chen, E. Prakash, H.-C. Hsu, H.-Y. Huang, M.-T. Lin, K.-J. Chang, and M.-L. Kuo Connective Tissue Growth Factor Confers Drug Resistance in Breast Cancer through Concomitant Up-regulation of Bcl-xL and cIAP1 Cancer Res., April 15, 2009; 69(8): 3482 - 3491. [Abstract] [Full Text] [PDF]

				A. Coxon, T. Bush, D. Saffran, S. Kaufman, B. Belmontes, K. Rex, P. Hughes, S. Caenepeel, J. B. Rottman, A. Tasker, et al. Broad Antitumor Activity in Breast Cancer Xenografts by Motesanib, a Highly Selective, Oral Inhibitor of Vascular Endothelial Growth Factor, Platelet-Derived Growth Factor, and Kit Receptors Clin. Cancer Res., January 1, 2009; 15(1): 110 - 118. [Abstract] [Full Text] [PDF]

				S. Welter, J. Jacobs, T. Krbek, M. Totsch, and G. Stamatis Pulmonary metastases of breast cancer. When is resection indicated? Eur. J. Cardiothorac. Surg., December 1, 2008; 34(6): 1228 - 1234. [Abstract] [Full Text] [PDF]

				M. Cristofanilli, P. Morandi, S. Krishnamurthy, J. M. Reuben, B.-N. Lee, D. Francis, D. J. Booser, M. C. Green, B. K. Arun, L. Pusztai, et al. Imatinib mesylate (Gleevec(R)) in advanced breast cancer-expressing C-Kit or PDGFR-{beta}: clinical activity and biological correlations Ann. Onc., October 1, 2008; 19(10): 1713 - 1719. [Abstract] [Full Text] [PDF]

				W. J. Gradishar, J. R. Bellon, M. A. Gadd, H. A. D'Alessandro, and K. Braaten Case 30-2008 -- A 47-Year-Old Woman with a Mass in the Breast and a Solitary Lesion in the Spine N. Engl. J. Med., September 25, 2008; 359(13): 1382 - 1391. [Full Text] [PDF]

				T. Landemaine, A. Jackson, A. Bellahcene, N. Rucci, S. Sin, B. M. Abad, A. Sierra, A. Boudinet, J.-M. Guinebretiere, E. Ricevuto, et al. A Six-Gene Signature Predicting Breast Cancer Lung Metastasis Cancer Res., August 1, 2008; 68(15): 6092 - 6099. [Abstract] [Full Text] [PDF]

				A. Vultur, R. Buettner, C. Kowolik, W. Liang, D. Smith, F. Boschelli, and R. Jove SKI-606 (bosutinib), a novel Src kinase inhibitor, suppresses migration and invasion of human breast cancer cells Mol. Cancer Ther., May 1, 2008; 7(5): 1185 - 1194. [Abstract] [Full Text] [PDF]

				M. Crump, S. Gluck, D. Tu, D. Stewart, M. Levine, P. Kirkbride, J. Dancey, S. O'Reilly, T. Shore, S. Couban, et al. Randomized Trial of High-Dose Chemotherapy With Autologous Peripheral-Blood Stem-Cell Support Compared With Standard-Dose Chemotherapy in Women With Metastatic Breast Cancer: NCIC MA.16 J. Clin. Oncol., January 1, 2008; 26(1): 37 - 43. [Abstract] [Full Text] [PDF]

				M. Colozza, E. de Azambuja, N. Personeni, F. Lebrun, M. J. Piccart, and F. Cardoso Achievements in Systemic Therapies in the Pregenomic Era in Metastatic Breast Cancer Oncologist, March 1, 2007; 12(3): 253 - 270. [Abstract] [Full Text] [PDF]

				N. Rucci, I. Recchia, A. Angelucci, M. Alamanou, A. Del Fattore, D. Fortunati, M. Susa, D. Fabbro, M. Bologna, and A. Teti Inhibition of Protein Kinase c-Src Reduces the Incidence of Breast Cancer Metastases and Increases Survival in Mice: Implications for Therapy J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 161 - 172. [Abstract] [Full Text] [PDF]

				J. B Engel, A. V Schally, G. Halmos, B. Baker, A. Nagy, and G. Keller Targeted cytotoxic bombesin analog AN-215 effectively inhibits experimental human breast cancers with a low induction of multi-drug resistance proteins Endocr. Relat. Cancer, December 1, 2005; 12(4): 999 - 1009. [Abstract] [Full Text] [PDF]

				E. C. McLemore, B. A. Pockaj, C. Reynolds, R. J. Gray, J. L. Hernandez, C. S. Grant, and J. H. Donohue Breast Cancer: Presentation and Intervention in Women With Gastrointestinal Metastasis and Carcinomatosis Ann. Surg. Oncol., November 1, 2005; 12(11): 886 - 894. [Abstract] [Full Text] [PDF]

				J. O'Shaughnessy Extending Survival with Chemotherapy in Metastatic Breast Cancer Oncologist, October 1, 2005; 10(suppl_3): 20 - 29. [Abstract] [Full Text] [PDF]

				N. K. Ibrahim, B. Samuels, R. Page, D. Doval, K. M. Patel, S.C. Rao, M. K. Nair, P. Bhar, N. Desai, and G. N. Hortobagyi Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer J. Clin. Oncol., September 1, 2005; 23(25): 6019 - 6026. [Abstract] [Full Text] [PDF]

				P. Bruzzi, L. Del Mastro, M. P. Sormani, L. Bastholt, M. Danova, C. Focan, G. Fountzilas, J. Paul, R. Rosso, and M. Venturini Objective Response to Chemotherapy As a Potential Surrogate End Point of Survival in Metastatic Breast Cancer Patients J. Clin. Oncol., August 1, 2005; 23(22): 5117 - 5125. [Abstract] [Full Text] [PDF]

				C. Zielinski, S. Beslija, Z. Mrsic-Krmpotic, M. Welnicka-Jaskiewicz, C. Wiltschke, Z. Kahan, M. Grgic, V. Tzekova, M. Inbar, J. Cervek, et al. Gemcitabine, Epirubicin, and Paclitaxel Versus Fluorouracil, Epirubicin, and Cyclophosphamide As First-Line Chemotherapy in Metastatic Breast Cancer: A Central European Cooperative Oncology Group International, Multicenter, Prospective, Randomized Phase III Trial J. Clin. Oncol., March 1, 2005; 23(7): 1401 - 1408. [Abstract] [Full Text] [PDF]

				M. Cristofanilli, D. F. Hayes, G. T. Budd, M. J. Ellis, A. Stopeck, J. M. Reuben, G. V. Doyle, J. Matera, W. J. Allard, M. C. Miller, et al. Circulating Tumor Cells: A Novel Prognostic Factor for Newly Diagnosed Metastatic Breast Cancer J. Clin. Oncol., March 1, 2005; 23(7): 1420 - 1430. [Abstract] [Full Text] [PDF]

				K. D. Miller, L. I. Chap, F. A. Holmes, M. A. Cobleigh, P. K. Marcom, L. Fehrenbacher, M. Dickler, B. A. Overmoyer, J. D. Reimann, A. P. Sing, et al. Randomized Phase III Trial of Capecitabine Compared With Bevacizumab Plus Capecitabine in Patients With Previously Treated Metastatic Breast Cancer J. Clin. Oncol., February 1, 2005; 23(4): 792 - 799. [Abstract] [Full Text] [PDF]

				P. Schmid, W. Schippinger, T. Nitsch, G. Huebner, V. Heilmann, W. Schultze, H. Hausmaninger, M. Wischnewsky, and K. Possinger Up-Front Tandem High-Dose Chemotherapy Compared With Standard Chemotherapy With Doxorubicin and Paclitaxel in Metastatic Breast Cancer: Results of a Randomized Trial J. Clin. Oncol., January 20, 2005; 23(3): 432 - 440. [Abstract] [Full Text] [PDF]

				C. Bernard-Marty, F. Cardoso, and M. J. Piccart Facts and Controversies in Systemic Treatment of Metastatic Breast Cancer Oncologist, November 1, 2004; 9(6): 617 - 632. [Abstract] [Full Text] [PDF]

				R. C. F. Leonard, M. Lind, C. Twelves, R. Coleman, S. van Belle, C. Wilson, J. Ledermann, I. Kennedy, P. Barrett-Lee, T. Perren, et al. Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensification Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial J Natl Cancer Inst, July 21, 2004; 96(14): 1076 - 1083. [Abstract] [Full Text] [PDF]

				E. Alba, M. Martin, M. Ramos, E. Adrover, A. Balil, C. Jara, A. Barnadas, A. Fernandez-Aramburo, P. Sanchez-Rovira, M. Amenedo, et al. Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study J. Clin. Oncol., July 1, 2004; 22(13): 2587 - 2593. [Abstract] [Full Text] [PDF]

				W. J. Gradishar Tamoxifen--What Next? Oncologist, July 1, 2004; 9(4): 378 - 384. [Abstract] [Full Text] [PDF]

				A. Alexopoulos, M. V. Karamouzis, H. Stavrinides, A. Ardavanis, K. Kandilis, J. Stavrakakis, C. Georganta, and G. Rigatos Phase II study of pegylated liposomal doxorubicin (Caelyx(R)) and docetaxel as first-line treatment in metastatic breast cancer Ann. Onc., June 1, 2004; 15(6): 891 - 895. [Abstract] [Full Text] [PDF]

				S.-C. J. Lin, K.-F. Lee, A. Yu. Nikitin, S. G. Hilsenbeck, R. D. Cardiff, A. Li, K.-W. Kang, S. A. Frank, W.-H. Lee, and E. Y-H. P. Lee Somatic Mutation of p53 Leads to Estrogen Receptor {alpha}-Positive and -Negative Mouse Mammary Tumors with High Frequency of Metastasis Cancer Res., May 15, 2004; 64(10): 3525 - 3532. [Abstract] [Full Text] [PDF]

				C. T. Chung and R. W. Carlson Goals and Objectives in the Management of Metastatic Breast Cancer Oncologist, December 1, 2003; 8(6): 514 - 520. [Abstract] [Full Text] [PDF]

				H. Lapillonne, M. Konopleva, T. Tsao, D. Gold, T. McQueen, R. L. Sutherland, T. Madden, and M. Andreeff Activation of Peroxisome Proliferator-activated Receptor {gamma} by a Novel Synthetic Triterpenoid 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic Acid Induces Growth Arrest and Apoptosis in Breast Cancer Cells Cancer Res., September 15, 2003; 63(18): 5926 - 5939. [Abstract] [Full Text] [PDF]

				S. E. Singletary, G. Walsh, J.-N. Vauthey, S. Curley, R. Sawaya, K. L. Weber, F. Meric, and G. N. Hortobagyi A Role for Curative Surgery in the Treatment of Selected Patients with Metastatic Breast Cancer Oncologist, June 1, 2003; 8(3): 241 - 251. [Abstract] [Full Text] [PDF]

				V. Valero and G. N. Hortobagyi Are Anthracycline-Taxane Regimens the New Standard of Care in the Treatment of Metastatic Breast Cancer? J. Clin. Oncol., March 15, 2003; 21(6): 959 - 962. [Full Text] [PDF]

				J.-M. Nabholtz, C. Falkson, D. Campos, J. Szanto, M. Martin, S. Chan, T. Pienkowski, J. Zaluski, T. Pinter, M. Krzakowski, et al. Docetaxel and Doxorubicin Compared With Doxorubicin and Cyclophosphamide as First-Line Chemotherapy for Metastatic Breast Cancer: Results of a Randomized, Multicenter, Phase III Trial J. Clin. Oncol., March 15, 2003; 21(6): 968 - 975. [Abstract] [Full Text] [PDF]

				F. J. Esteva, J. Glaspy, S. Baidas, L. Laufman, L. Hutchins, M. Dickler, D. Tripathy, R. Cohen, A. DeMichele, R. C. Yocum, et al. Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer J. Clin. Oncol., March 15, 2003; 21(6): 999 - 1006. [Abstract] [Full Text] [PDF]

				B. Overmoyer Combination Chemotherapy for Metastatic Breast Cancer: Reaching for the Cure J. Clin. Oncol., February 15, 2003; 21(4): 580 - 582. [Full Text] [PDF]

				E. Heidemann, H. Stoeger, R. Souchon, W.-D. Hirschmann, H. Bodenstein, C. Oberhoff, J. T. Fischer, M. Schulze, M. Clemens, R. Andreesen, et al. Is first-line single-agent mitoxantrone in the treatment of high-risk metastatic breast cancer patients as effective as combination chemotherapy? No difference in survival but higher quality of life were found in a multicenter randomized trial Ann. Onc., November 1, 2002; 13(11): 1717 - 1729. [Abstract] [Full Text] [PDF]

				D. Osoba, D. J. Slamon, M. Burchmore, and M. Murphy Effects on Quality of Life of Combined Trastuzumab and Chemotherapy in Women With Metastatic Breast Cancer J. Clin. Oncol., July 15, 2002; 20(14): 3106 - 3113. [Abstract] [Full Text] [PDF]

				P. Vici, G. Colucci, V. Gebbia, A. Amodio, F. Giotta, F. Belli, F. Conti, N. Gebbia, G. Pezzella, M. R. Valerio, et al. First-Line Treatment With Epirubicin and Vinorelbine in Metastatic Breast Cancer J. Clin. Oncol., June 1, 2002; 20(11): 2689 - 2694. [Abstract] [Full Text] [PDF]

				M. Pawlicki, J. Rolski, J. Zaluski, P. Siedlecki, C. Ramlau, and P. Tomzak A Phase II Study of Intravenous Navelbine and Doxorubicin Combination in Previously Untreated Advanced Breast Carcinoma Oncologist, June 1, 2002; 7(3): 205 - 209. [Abstract] [Full Text] [PDF]

				A. Schneeweiss, M. Hensel, P. Sinn, T. Khbeis, R. Haas, G. Bastert, and A. D. Ho Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose Ann. Onc., May 1, 2002; 13(5): 679 - 688. [Abstract] [Full Text] [PDF]

				M. Venturini, L. Del Mastro, O. Garrone, C. Angiolini, M. Merlano, M. Bergaglio, G. Tolino, A. Lambiase, A. Baldini, G. Canavese, et al. Phase I, dose-finding study of capecitabine in combination with docetaxel and epirubicin as first-line chemotherapy for advanced breast cancer Ann. Onc., April 1, 2002; 13(4): 546 - 552. [Abstract] [Full Text] [PDF]

				F. Cardoso, A. Di Leo, C. Lohrisch, C. Bernard, F. Ferreira, and M. J. Piccart Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades? Ann. Onc., February 20, 2002; 13(2): 197 - 207. [Abstract] [Full Text] [PDF]

				G. N. Hortobagyi Can We Cure Limited Metastatic Breast Cancer? J. Clin. Oncol., February 1, 2002; 20(3): 620 - 623. [Full Text] [PDF]

				Y. Nieto, S. Nawaz, R. B. Jones, E. J. Shpall, P. J. Cagnoni, P. A. McSweeney, A. Baron, C. Razook, S. Matthes, and S. I. Bearman Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer J. Clin. Oncol., February 1, 2002; 20(3): 707 - 718. [Abstract] [Full Text] [PDF]

				J. A. Lawrence, P. C. Adamson, R. Caruso, C. Chow, D. Kleiner, R. F. Murphy, D. J. Venzon, M. Shovlin, M. Noone, M. Merino, et al. Phase I Clinical Trial of Alitretinoin and Tamoxifen in Breast Cancer Patients: Toxicity, Pharmacokinetic, and Biomarker Evaluations J. Clin. Oncol., May 15, 2001; 19(10): 2754 - 2763. [Abstract] [Full Text] [PDF]

				F. J. Esteva, V. Valero, L. Pusztai, L. Boehnke-Michaud, A. U. Buzdar, and G. N. Hortobagyi Chemotherapy of Metastatic Breast Cancer: What to Expect in 2001 and Beyond Oncologist, April 1, 2001; 6(2): 133 - 146. [Abstract] [Full Text]

				J. Jassem, T. Pienkowski, A. Pluzanska, S. Jelic, V. Gorbunova, Z. Mrsic-Krmpotic, J. Berzins, T. Nagykalnai, N. Wigler, J. Renard, et al. Doxorubicin and Paclitaxel Versus Fluorouracil, Doxorubicin, and Cyclophosphamide as First-Line Therapy for Women With Metastatic Breast Cancer: Final Results of a Randomized Phase III Multicenter Trial J. Clin. Oncol., March 15, 2001; 19(6): 1707 - 1715. [Abstract] [Full Text] [PDF]

				D. J. Slamon, B. Leyland-Jones, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, T. Fleming, W. Eiermann, J. Wolter, M. Pegram, et al. Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2 N. Engl. J. Med., March 15, 2001; 344(11): 783 - 792. [Abstract] [Full Text] [PDF]

				R. A. Brito, V. Valero, A. U. Buzdar, D. J. Booser, F. Ames, E. Strom, M. Ross, R. L. Theriault, D. Frye, S.-W. Kau, et al. Long-Term Results of Combined-Modality Therapy for Locally Advanced Breast Cancer With Ipsilateral Supraclavicular Metastases: The University of Texas M.D. Anderson Cancer Center Experience J. Clin. Oncol., February 1, 2001; 19(3): 628 - 633. [Abstract] [Full Text] [PDF]

				A. Schneeweiss, M. Hensel, R. Goerner, T. Khbeis, S. Hohaus, G. Egerer, E. Solomayer, R. Haas, E.-M. Grischke, G. Bastert, et al. Comparison of Double and Triple High-Dose Chemotherapy with Autologous Blood Stem Cell Transplantation in Patients with Metastatic Breast Cancer Stem Cells, February 1, 2001; 19(2): 151 - 160. [Abstract] [Full Text]

				M. Ando, T. Watanabe, K. Nagata, M. Narabayashi, I. Adachi, and N. Katsumata Efficacy of Docetaxel 60 mg/m2 in Patients With Metastatic Breast Cancer According to the Status of Anthracycline Resistance J. Clin. Oncol., January 15, 2001; 19(2): 336 - 342. [Abstract] [Full Text] [PDF]

				S. Rodenhuis The Status of High-Dose Chemotherapy in Breast Cancer Oncologist, October 1, 2000; 5(5): 369 - 375. [Abstract] [Full Text]

				Epirubicin-Based Chemotherapy in Metastatic Breast Cancer Patients: Role of Dose-Intensity and Duration of Treatment J. Clin. Oncol., September 17, 2000; 18(17): 3115 - 3124. [Abstract] [Full Text] [PDF]

				C. Tempfer, M. Seifert, T. Brodowicz, L. Auerbach, C. Zielinski, P. Iacopino, S. Palazzo, F. Patrone, E. A. Stadtmauer, L. J. Goldstein, et al. High-Dose Chemotherapy plus Hematopoietic Stem-Cell Rescue for Metastatic Breast Cancer N. Engl. J. Med., August 10, 2000; 343(6): 439 - 441. [Full Text]

				T. Gilewski, S. Adluri, G. Ragupathi, S. Zhang, T.-J. Yao, K. Panageas, M. Moynahan, A. Houghton, L. Norton, and P. O. Livingston Vaccination of High-Risk Breast Cancer Patients with Mucin-1 (MUC1) Keyhole Limpet Hemocyanin Conjugate plus QS-21 Clin. Cancer Res., May 1, 2000; 6(5): 1693 - 1701. [Abstract] [Full Text]

				E. A. Stadtmauer, A. O'Neill, L. J. Goldstein, P. A. Crilley, K. F. Mangan, J. N. Ingle, I. Brodsky, S. Martino, H. M. Lazarus, J. K. Erban, et al. Conventional-Dose Chemotherapy Compared with High-Dose Chemotherapy plus Autologous Hematopoietic Stem-Cell Transplantation for Metastatic Breast Cancer N. Engl. J. Med., April 13, 2000; 342(15): 1069 - 1076. [Abstract] [Full Text] [PDF]

				J. Alexandre, P. Bleuzen, J. Bonneterre, W. Sutherland, J. L. Misset, J.-P. Guastalla, P. Viens, S. Faivre, A. Chahine, M. Spielman, et al. Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients J. Clin. Oncol., February 1, 2000; 18(3): 562 - 562. [Abstract] [Full Text] [PDF]

				R. B. Weiss The Randomized Trials of Dose-Intensive Therapy for Breast Cancer: What Do They Mean for Patient Care and Where Do We Go From Here? Oncologist, December 1, 1999; 4(6): 450 - 458. [Abstract] [Full Text]

				K. H. Antman, D. F. Heitjan, and G. N. Hortobagyi High-Dose Chemotherapy for Breast Cancer JAMA, November 10, 1999; 282(18): 1701 - 1703. [Full Text] [PDF]

				A. Gennari, B. Salvadori, S. Donati, C. Bengala, C. Orlandini, R. Danesi, M. Del Tacca, P. Bruzzi, and P. F. Conte Cardiotoxicity of Epirubicin/Paclitaxel-Containing Regimens: Role of Cardiac Risk Factors J. Clin. Oncol., November 1, 1999; 17(11): 3596 - 3602. [Abstract] [Full Text] [PDF]

				R. Livingston and J. Crowley Commentary on PBT-1 Study of High-Dose Consolidation Versus Standard Therapy in Metastatic Breast Cancer J. Clin. Oncol., November 1, 1999; 17(90001): 22 - 24. [Full Text] [PDF]

				P. A. Rowlings, S. F. Williams, K. H. Antman, K. K. Fields, J. W. Fay, E. Reed, C. J. Pelz, J. P. Klein, K. A. Sobocinski, M. J. Kennedy, et al. Factors Correlated With Progression-Free Survival After High-Dose Chemotherapy and Hematopoietic Stem Cell Transplantation for Metastatic Breast Cancer JAMA, October 13, 1999; 282(14): 1335 - 1343. [Abstract] [Full Text] [PDF]

				D. A. Rizzieri, J. J. Vredenburgh, R. Jones, M. Ross, E. J. Shpall, A. Hussein, G. Broadwater, D. Berry, W. P. Petros, C. Gilbert, et al. Prognostic and Predictive Factors for Patients With Metastatic Breast Cancer Undergoing Aggressive Induction Therapy Followed by High-Dose Chemotherapy With Autologous Stem-Cell Support J. Clin. Oncol., October 1, 1999; 17(10): 3064 - 3074. [Abstract] [Full Text] [PDF]

				E. Abruzzese, J. E. Radford, J. S. Miller, J. J. Vredenburgh, P. N. Rao, M. J. Pettenati, J. M. Cruz, J. J. Perry, S. Amadori, and D. D. Hurd Detection of Abnormal Pretransplant Clones in Progenitor Cells of Patients Who Developed Myelodysplasia After Autologous Transplantation Blood, September 1, 1999; 94(5): 1814 - 1819. [Abstract] [Full Text] [PDF]

				Y. Nieto, P. J. Cagnoni, E. J. Shpall, S. Matthes, A. Baron, R. B. Jones, and S. I. Bearman Phase II Trial of High-Dose Chemotherapy with Autologous Stem Cell Transplant for Stage IV Breast Cancer with Minimal Metastatic Disease Clin. Cancer Res., July 1, 1999; 5(7): 1731 - 1737. [Abstract] [Full Text] [PDF]

				G. N. Hortobagyi Treatment of Breast Cancer N. Engl. J. Med., October 1, 1998; 339(14): 974 - 984. [Full Text] [PDF]

				S. Subramanyan and M. J. Kennedy Breast Cancer: High-Dose Therapy Oncologist, October 1, 1998; 3(5): 289 - 299. [Abstract] [Full Text]

				Prolonged Survival after Chemotherapy for Metastatic Breast Cancer Journal Watch Women's Health, October 1, 1996; 1996(1001): 16 - 16. [Full Text]

				LONG-TERM SURVIVAL AFTER CHEMOTHERAPY FOR METASTATIC BREAST CANCER Journal Watch (General), August 20, 1996; 1996(820): 1 - 1. [Full Text]